Skip to main content

Advertisement

SpringerLink
Log in

High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort

  • Original Article - Observational Research
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

To evaluate initial glucocorticoid (GC) therapy in patients with rheumatoid arthritis (RA). Six hundred sixty-nine patients with early RA were followed for 2 years in the multicenter “Course And Prognosis of Early Arthritis” cohort. Treatment was applied according to routine care. Assessments included disease activity (DAS28), disability Hannover Functional Status Questionnaire (FFbH), and treatment details. Mixed models, ANCOVA, and logistic regression models were used for statistical analysis. In total, 518 patients (77 %) received oral GCs at baseline; 20 % received a low dose (<7.5 mg prednisolone/day), 22 % received a moderate (7.5–19 mg), and 35 % received a high dose (≥20 mg). In a multivariate logistic regression analysis, higher DAS28 values (OR 1.3) were associated with the use of higher GC doses at baseline (p < 0.001). After adjusting for age, sex, and baseline DAS28 and DMARDs, the patients who started with high-dose GCs had a greater improvement in DAS28 (month 3) and FFbH (month 6, p < 0.001 each). At 2 years, the mean DAS28 remission rates and FFbH values were similar. In all GC groups, the mean dose was tapered to 4 mg/day within 6 months. The reported comorbidities were not increased in patients with high-dose GC therapy. Starting treatment with high-dose GCs led to a better clinical response within 3 to 6 months compared to starting patients on lower dosages. Irrespective of the starting approach, rheumatologists tapered GCs down to a low dose within 6 months. With this strategy, clinical outcomes at 2 years did not differ relevantly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Smolen JS, Aletaha D, Machold KP (2005) Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 19(1):163–177

    Article  CAS  PubMed  Google Scholar 

  2. van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH (2014) What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 73(5):861–870

    Article  PubMed  Google Scholar 

  3. Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Albrecht K, Kruger K, Wollenhaupt J et al (2014) German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int 34(1):1–9

    Article  CAS  PubMed  Google Scholar 

  5. Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639

    Article  CAS  Google Scholar 

  6. NICE (National Institute for Health And Care Excellence) (August 2013) Rheumatoid Arthritis. The management of rheumatoid arthritis in adults. http://www.nice.org.uk/nicemedia/live/12131/43327/43327.pdf. Accessed Aug 2013

  7. Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72(12):1905–1913

    Article  CAS  PubMed  Google Scholar 

  8. Gaujoux-Viala C, Nam J, Ramiro S et al (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73(3):510–515

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Rau R (2014) Glucocorticoid treatment in rheumatoid arthritis. Expert Opin Pharmacother 15(11):1575–1583

    Article  CAS  PubMed  Google Scholar 

  10. Boers M, van Tuyl PJ, van den Broek M, Kostense PJ, Allaart CF (2013) Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also ‘disconnect’ disease activity and damage in rheumatoid arthritis. Ann Rheum Dis 72(3):406–409

    Article  CAS  PubMed  Google Scholar 

  11. Montecucco C, Todoerti M, Sakellariou G, Scire CA, Caporali R (2012) Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 14(3):R112

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Svensson B, Hafstrom I (2011) Effects on joint destruction and remission, bone turnover and lack of influence on atherogenesis: a review of the BARFOT low-dose prednisolone studies on patients with early RA. Clin Exp Rheumatol 29(5 Suppl 68):S63–S67

    CAS  PubMed  Google Scholar 

  13. Nam JL, Villeneuve E, Hensor EM et al (2014) Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 73(1):75–85

    Article  CAS  PubMed  Google Scholar 

  14. Hetland ML, Horslev-Petersen K (2012) The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arthritis. Clin Exp Rheumatol 30(4 Suppl 73):S44–S49

    PubMed  Google Scholar 

  15. de Jong PH, Hazes JM, Barendregt PJ et al (2013) Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 72(1):72–78

    Article  PubMed  Google Scholar 

  16. Bakker MF, Jacobs JW, Welsing PM et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156(5):329–339

    Article  PubMed  Google Scholar 

  17. Gossec L, Paternotte S, Aanerud GJ et al (2011) Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis 70(6):935–942

    Article  CAS  PubMed  Google Scholar 

  18. Lautenschlaeger J, Mau W, Kohlmann T et al (1997) [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire] German. Z Rheumatol 56(3):144–155

    Article  Google Scholar 

  19. Boyd TA, Bonner A, Thorne C et al (2013) The relationship between function and disease activity as measured by the HAQ and DAS28 varies over time and by Rheumatoid factor status in early inflammatory arthritis (EIA). Results from the CATCH Cohort. Open Rheumatol J 7:58–63

    Article  PubMed Central  PubMed  Google Scholar 

  20. Combe B, Rincheval N, Benessiano J et al (2013) Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol 40(10):1650–1657

    Article  CAS  PubMed  Google Scholar 

  21. Svensson B, Andersson ML, Bala SV, Forslind K, Hafstrom I (2013) Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. BMJ Open 3(9):e003554

    Article  PubMed Central  PubMed  Google Scholar 

  22. McKeown E, Bykerk VP, De Leon F et al (2012) Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology (Oxford) 51(9):1662–1669

    Article  CAS  Google Scholar 

  23. Cardiel MH, Pons-Estel BA, Sacnun MP et al (2012) Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience. J Clin Rheumatol 18(7):327–335

    Article  PubMed  Google Scholar 

  24. Wassenberg S, Rau R, Zeidler H (2011) A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis-the low-dose prednisolone trial. Clin Exp Rheumatol 29(5 Suppl 68):S68–S72

    CAS  PubMed  Google Scholar 

  25. Buttgereit F, Mehta D, Kirwan J et al (2013) Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 72(2):204–210

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge the contribution of the participating patients and the consultant rheumatologists for recruiting and following the patients in the CAPEA cohort. The authors also acknowledge the support of Winicker Norimed in data collection and monitoring and the contributions of Edmund Edelmann, MD, Bad Aibling and Georg Schett, MD, Erlangen as members of the advisory board. Authors received the Support by an unconditional grant from Pfizer, Germany.

Conflict of interest

The authors report grants from Pfizer, Germany, during the conduct of the study; J Callhoff reports personal fees from Pfizer, Germany, outside the submitted work; M. Schneider has nothing to disclose.

Author information

Authors and Affiliations

  1. German Rheumatism Research Centre, A Leibniz Institute, Epidemiology Unit, Charitéplatz 1, 10117, Berlin, Germany

    Katinka Albrecht, Johanna Callhoff & Angela Zink

  2. Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany

    Matthias Schneider

Authors
  1. Katinka Albrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johanna Callhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angela Zink
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katinka Albrecht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albrecht, K., Callhoff, J., Schneider, M. et al. High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort. Rheumatol Int 35, 1377–1384 (2015). https://doi.org/10.1007/s00296-015-3229-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-015-3229-x

Keywords

Search

Navigation